Skip to main content
Top
Published in: Infectious Diseases and Therapy 1/2021

Open Access 01-03-2021 | Minocycline | Case Series

Salvage Treatment with Cefiderocol Regimens in Two Intravascular Foreign Body Infections by MDR Gram-Negative Pathogens, Involving Non-Removable Devices

Authors: Marta Bodro, Marta Hernández-Meneses, Juan Ambrosioni, Laura Linares, Asunción Moreno, Elena Sandoval, Pol Olivas, María Hernández-Tejero, José M. Miró, Francesc Marco, Alex Soriano

Published in: Infectious Diseases and Therapy | Issue 1/2021

Login to get access

Abstract

Introduction

The objective of this study was to describe two challenging cases of intravascular foreign body infections caused by multidrug-resistant Gram-negative pathogens requiring complex antimicrobial regimens including cefiderocol and successfully treated without implant removal.

Methods

Clinical charts and microbiological reports of the clinical cases.

Results

Case 1 included a left ventricular assist device (HEARTMATE 3™Abbot®) infection due to Achromobacter xylosoxidans, while case 2 included a portal prosthesis infection due to Pseudomonas aeruginosa. As the pathogens were multidrug-resistant (MDR), both cases required antimicrobial regimens with cefiderocol; treatment was successful without implant removal. Importantly, case 1 presented a probable, drug-induced thrombocytopenia, a non-previously described side effect related to cefiderocol.

Conclusion

Cefiderocol may be an additional, promising drug to the available arsenal, even for challenging foreign body infections caused by MDR Gram-negative pathogens.
Literature
1.
go back to reference Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215:S28-36.CrossRef Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215:S28-36.CrossRef
2.
go back to reference Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol. 2015;71:801–10.CrossRef Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol. 2015;71:801–10.CrossRef
3.
go back to reference Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60:AAC.01405-16.CrossRef Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60:AAC.01405-16.CrossRef
5.
go back to reference Jacobs MR, Abdelhamed AM, Good CE, Rhoads DD, Hujer KM, Hujer AM, et al. ARGONAUT-I: activity of cefiderocol (S-649266), a siderophore cephalosporin, against gram-negative bacteria, including carbapenem-resistant nonfermenters and enterobacteriaceae with defined extended-spectrum β-lactamases and carbapenemases. Antimicrob Agents Chemother. 2018;63(1):e01801–18.CrossRef Jacobs MR, Abdelhamed AM, Good CE, Rhoads DD, Hujer KM, Hujer AM, et al. ARGONAUT-I: activity of cefiderocol (S-649266), a siderophore cephalosporin, against gram-negative bacteria, including carbapenem-resistant nonfermenters and enterobacteriaceae with defined extended-spectrum β-lactamases and carbapenemases. Antimicrob Agents Chemother. 2018;63(1):e01801–18.CrossRef
6.
go back to reference Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ, Hellenic Cefiderocol Study Group. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. J Antimicrob Chemother. 2017;72:1704–8.CrossRef Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ, Hellenic Cefiderocol Study Group. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. J Antimicrob Chemother. 2017;72:1704–8.CrossRef
7.
go back to reference Yamano Y. In vitro activity of cefiderocol against a broad range of clinically important gram-negative bacteria. Clin Infect Dis. 2019;69(Suppl 7):S544–51.CrossRef Yamano Y. In vitro activity of cefiderocol against a broad range of clinically important gram-negative bacteria. Clin Infect Dis. 2019;69(Suppl 7):S544–51.CrossRef
8.
go back to reference Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, Sahm DF. In Vitro Activity Of Cefiderocol, A Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated By Clinical Laboratories in North America and Europe in 2015–2016: SIDERO-WT-2015. Int J Antimicrob Agents. 2019;53:456–66.CrossRef Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, Sahm DF. In Vitro Activity Of Cefiderocol, A Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated By Clinical Laboratories in North America and Europe in 2015–2016: SIDERO-WT-2015. Int J Antimicrob Agents. 2019;53:456–66.CrossRef
9.
go back to reference Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2018;62(2):e01968–17.PubMedPubMedCentral Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2018;62(2):e01968–17.PubMedPubMedCentral
10.
go back to reference Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolau DP. Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of gram-negative bacteria in a murine thigh infection model. Antimicrob Agents Chemother. 2017;61(11):e01022–17.PubMedPubMedCentral Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolau DP. Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of gram-negative bacteria in a murine thigh infection model. Antimicrob Agents Chemother. 2017;61(11):e01022–17.PubMedPubMedCentral
11.
go back to reference Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18:1319–28.CrossRef Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18:1319–28.CrossRef
12.
go back to reference Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis [Internet]. 2020 [cited 2020 Nov 23]; https://linkinghub.elsevier.com/retrieve/pii/S1473309920307313. Accessed 24 Nov 2020. Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis [Internet]. 2020 [cited 2020 Nov 23]; https://​linkinghub.​elsevier.​com/​retrieve/​pii/​S147330992030731​3. Accessed 24 Nov 2020.
13.
go back to reference Kazmierczak KM, Tsuji M, Wise MG, Hackel M, Yamano Y, Echols R, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014. Int J Antimicrob Agents. 2019;53:177–84.CrossRef Kazmierczak KM, Tsuji M, Wise MG, Hackel M, Yamano Y, Echols R, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014. Int J Antimicrob Agents. 2019;53:177–84.CrossRef
14.
go back to reference Trecarichi EM, Quirino A, Scaglione V, Longhini F, Garofalo E, Bruni A, et al. Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report. J Antimicrob Chemother [Internet]. 2019 [cited 2019 Oct 25];74:3399–401. http://www.ncbi.nlm.nih.gov/pubmed/31369095. Accessed 24 Nov 2020. Trecarichi EM, Quirino A, Scaglione V, Longhini F, Garofalo E, Bruni A, et al. Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report. J Antimicrob Chemother [Internet]. 2019 [cited 2019 Oct 25];74:3399–401. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​31369095. Accessed 24 Nov 2020.
15.
16.
go back to reference Pybus CA, Felder-Scott C, Obuekwe V, Greenberg DE. Cefiderocol retains anti-biofilm activity in multi-drug resistant gram-negative pathogens. Antimicrob Agents Chemother [Internet]. Antimicrob Agents Chemother; 2020 [cited 2020 Nov 24]; http://www.ncbi.nlm.nih.gov/pubmed/33199383. Accessed 24 Nov 2020. Pybus CA, Felder-Scott C, Obuekwe V, Greenberg DE. Cefiderocol retains anti-biofilm activity in multi-drug resistant gram-negative pathogens. Antimicrob Agents Chemother [Internet]. Antimicrob Agents Chemother; 2020 [cited 2020 Nov 24]; http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​33199383. Accessed 24 Nov 2020.
Metadata
Title
Salvage Treatment with Cefiderocol Regimens in Two Intravascular Foreign Body Infections by MDR Gram-Negative Pathogens, Involving Non-Removable Devices
Authors
Marta Bodro
Marta Hernández-Meneses
Juan Ambrosioni
Laura Linares
Asunción Moreno
Elena Sandoval
Pol Olivas
María Hernández-Tejero
José M. Miró
Francesc Marco
Alex Soriano
Publication date
01-03-2021
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 1/2021
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-020-00385-4

Other articles of this Issue 1/2021

Infectious Diseases and Therapy 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.